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Objectives: To investigate the regulation of sclerostin (SOST) in osteoarthritis (OA) and its potential effects
on articular cartilage degradation.
Methods: SOST and other Wnt-b-catenin components were immuno-localised in osteochondral sections
of surgically-induced OA in knees of sheep and mice, and human OA samples obtained at arthroplasty.
Regulation of SOST mRNA and protein expression by ovine chondrocytes in response to interleukin-1a
(IL-1a) or tumour necrosis factor-a (TNFa) was examined in explant cultures. The effect of 25 or 250 ng/
ml recombinant SOST alone or in combination with IL-1a, on ovine articular cartilage explant aggrecan
degradation, and chondrocyte gene expression of Wnt-b-catenin pathway proteins, metalloproteinases
and their inhibitors, and cartilage matrix proteins was quantiﬁed.
Results: Contrary to being an osteocyte-speciﬁc protein, SOST was expressed by articular chondrocytes,
and mRNA levels were upregulated in vitro by IL-1a but not TNFa. Chondrocyte SOST staining was
signiﬁcantly increased only in the focal area of cartilage damage in surgically-induced OA in sheep and
mice, as well as end-stage human OA. In contrast, osteocyte SOST was focally decreased in the
subchondral bone in sheep OA in association with bone sclerosis. SOST was biologically active in
chondrocytes, inhibiting Wnt-b-catenin signalling and catabolic metalloproteinase [matrix metal-
loproteinases (MMP) and distintegrin and metalloproteinase with thrombospndin repeats (ADAMTS)]
expression, but also decreasing mRNA levels of aggrecan, collagen II and tissue inhibitors of
metalloproteinaes (TIMPs). Despite this mixed effect, SOST dose-dependently inhibited IL-1a-stimulated
cartilage aggrecanolysis in vitro.
Conclusions: These results implicate SOST in regulating the OA disease processes, but suggest opposing
effects by promoting disease-associated subchondral bone sclerosis while inhibiting degradation of
cartilage.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The aetiology of knee osteoarthritis (OA) is multifactorial, and
although ageing is strongly associated, other factors contribute. In
particular altered biomechanics and joint instability commonly leads
to “post-traumatic OA” within 10e15 years after joint injury in
humans1,2. The central feature of OA is considered to be theChristopher Little, Raymond
ing e B6, Royal North Shore
C.B. Little).
s Research Society International. Pprogressive destruction of articular cartilage, however change occurs
in all joint tissues. Subchondral bone thickening and marginal
osteophytosis are classic features of OA, and together with synovitis
correlate with pain3. Focal loss of articular cartilage in OA may be
linked to changes in the subjacent bone, through altered load
transmission and/or direct signalling between the adjacent tissues4.
The Wnt-b-catenin signalling pathway has well-recognised roles
in embryologyanddevelopment, and is emerging as critical regulator
of bone and cartilage homeostasis in the adult5e8. Canonical Wnt
signalling is initiated by binding to frizzled receptors and co-
receptors, [low-density lipoprotein receptor (LRP)5/6], which leads
to b-catenin stabilization, nuclear translocation, and activation of
target genes such asWnt-induced signalling protein-1 (WISP-1).Wntublished by Elsevier Ltd. All rights reserved.
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(DKK1), secreted frizzled-related proteins (sFRPs), and sclerostin
(SOST)6. There is a large body of evidence demonstrating the central
role for Wnt signalling in regulating adult bone turnover, with
increased b-catenin activity inducingboneproduction, and inhibition
of soluble antagonists an emerging therapeutic approach for osteo-
porotic and inﬂammatory bone loss7,9. In adult cartilage in contrast,
increased Wnt-b-catenin stimulates tissue breakdown rather than
formation10. WISP-1 is increased in OA, and when over-expressed
induces cartilage degradation by upregulating matrix metal-
loproteinases (MMPs) and aggrecanases11. The pro-degradative
effects of Wnt-b-catenin are also driven through promotion of
chondrocyte hypertrophy and the associated up-regulation of
MMPs6,8. Induction of constitutive b-catenin activity in adult mouse
chondrocytes causes progressive cartilage degeneration and
increased subchondral bone density12. Circulating DKK1 levels
negatively correlate with biomarkers of cartilage breakdown in OA
patients13 and sFRP3 knockout mice have augmented cartilage
proteoglycan loss in a collagenase-induced instability model of
arthritis14.
Collectively this data suggests that elevated b-catenin activity is
a common mechanism in the excess bone formation and overlying
cartilage loss in OA. However, the complexity of Wnt-b-catenin
regulation and effects on joint tissues is demonstrated by the fact
that constitutive inhibition of chondrocyte b-catenin activity also
leads to OA in mice15. Increased circulating DKK1 (i.e., reducedWnt-
b-catenin) is associated with worse cartilage degradation in rheu-
matoid patients13. DKK1 promotes chondrocyte apoptosis in vitro16,
which may explain the reduction in severity in rat OA models with
systemic DKK1 inhibition17. The conﬂicting datawith DKK1 blockade
being chondroprotective while sFRP3 ablation augments chon-
drolysis, may suggest distinct roles for different Wnt inhibitors in
different tissues and/or disease states (e.g., degree of inﬂammation).
The effect on OA of blocking SOST, the other important soluble
inhibitor of Wnt signalling, has not been reported.
SOST, is a member of the DAN/Cerberus protein family and acts
to inhibit bone morphogenetic protein (BMP) secretion from cells
in which it is co-expressed, and as a potent inhibitor of canonical
Wnt signalling by binding to LRP5/618,19. It is the failure to inhibit
Wnt-b-catenin signalling that accounts for the characteristic high
bone density phenotypes in patients with homozygous defects in
SOST20, and in Sost knockout mice21. SOST expression is down
regulated by mechanical loading of bone22 but can be induced by
pro-inﬂammatory cytokines23,24, indicating that SOST can regulate
bothmechanical and inﬂammatory bone remodelling. There is little
information on changes in SOST in arthritis, with a reduction in the
number of SOST-positive osteocytes noted in association with
increased cortical bone density in the femoral neck of patients with
hip OA25, and in zygapophyseal joints with OA and ankylosing
spondylitis26. Recently it has been demonstrated that SOST is also
expressed by chondrocytes in mineralized cartilage27, and in
human end-stage OA28. To date there has been no analysis of
changes in SOST in subchondral bone in OA and how this relates to
the overlying cartilage damage. Furthermore, the regulation of
SOST expression by chondrocytes, the effects of SOST on chon-
drocytes and whether SOST plays any role in cartilage degradation
has not previously been studied. The aim of this study is to inves-
tigate these questions to better deﬁne the role of SOST in OA.
Materials and methods
Animal models and human specimens
Four-year-old castrated male Merino sheep underwent unilat-
eral medial meniscectomy (MEN) (n¼ 6) or a sham procedure(arthrotomy alone; n¼ 6) 3 months prior to euthanasia with
institutional ethics approval (AEC832R/00)29. Coronal 5 mm-thick
osteochondral specimens spanning the width of the medial tibial
plateau encompassing the region of maximal cartilage damage and
adjacent unaffected tissues, were ﬁxed for 24 h (10% neutral-
buffered formalin), decalciﬁed (10% formic acid/5% formalin) and
parafﬁn embedded30.
Ten-week-old male C57BL/6 mice underwent destabilization of
the medial meniscus (DMM) and sham surgery in right and left
knees, respectively31,32, with institutional ethics approval (proto-
cols 0051-005A and 0506-019A). Four mice were euthanised 1, 2
and 6 weeks after surgery. Sagittal sections every 40 mm across the
width of the medial femoro-tibial joint were evaluated33 enabling
intervening sections with maximal OA change to be used for
immunohistochemistry.
Human specimens were obtained with informed consent and
approval of the Northern Sydney Health Human Research Ethics
Committee, from patients undergoing total knee replacement for OA.
Sections (4 mm) from formalin-ﬁxed, decalciﬁed, parafﬁn-embedded
coronal osteochondral specimens spanning the width of the medial
tibial plateaus and encompassing the focal area of maximal cartilage
erosion from nine patients were immunostained (see below). Pooled
residual articular cartilage from the tibial plateauwas harvested from
an additional six patients and RNA extracted34.
Histopathology and immunohistochemistry
Sections from ovine joints were stained with toluidine blue and
fast green, and the cartilage degradation scored (BC and CBL) using
a previously described grading system30. The cartilage damage was
scored in two separate regions [Fig. 1(A)]: Area 1¼ unprotected,
and Area 2¼ normally protected by the meniscus, the latter expe-
riencing increased loading and degeneration following MEN while
Area 1 remains unaffected [Fig. 1(A)]35. The density of subchondral
bone in Area 1 and 2 was quantiﬁed from digital images of hae-
matoxylin and eosin-stained serial sections. A region of interest
1.1 mm wide 3.4 mm deep spanned the maximal depth of the
subchondral bone plate [chondro-osseous junction to the begin-
ning of trabecular bone (TB)]. The % of this area containing eosin-
stained bone was quantiﬁed (Image-Pro Plus 5.1; Media Cyber-
netics, Bethesda, USA), as a measure of “subchondral bone density”.
Sections for immunostaining were dewaxed and rehydrated,
and incubated in Protein-Block-Serum-Free (X909; DakoCytoma-
tion) for 10 min at room temperature. Sections were immuno-
localised overnight at 4C with primary antibody or non-immune
serum or IgG as negative controls, using conditions optimised
from preliminary studies: rabbit anti-SOST (Abcam, UK) 1.25 mg/ml;
goat anti-SOST (R&D systems, USA) and rabbit anti-WISP-1 (Santa
Cruz, USA) 1 mg/ml. Secondary antibody incubation and colour
development were performed as described35. Coded digital images
were evaluated independently by two observers (BC and CBL) and
the number of positively stained cells in each regionwas quantiﬁed.
The speciﬁcity of the anti-SOST antibody was demonstrated by pre-
absorptionwith 10 concentration of recombinant human SOST for
2 h at room temperature before routine immunohistochemistry.
Ex-vivo cartilage explants culture
Full-depth articular cartilage explants (5e10 mm2,w40 mg) from
the trochlear groove of 6e12-month-old ovine knee joints were
cultured in serum free media for 24 and 48 h 10 ng/ml IL-1a or
100 ng/ml tumour necrosis factor (TNFa) (PeproTech, Rocky Hill, NJ,
USA)36. The effect of SOSTwas examined by addition of 25 or 250 ng/
ml of rhSOST (R&D Systems, Minneapolis, USA) for 48 h 10 ng/ml
IL-1a. At harvest the explants were blotted dry, weighed, and snap-
Fig. 1. (A) Representative toluidine blue fast green stained section of a sheep tibial plateau 3 months post meniscectomy (MEN) showing the separate areas of cartilage with
adjacent subchondral bone (Area 1 & 2), and deeper TB examined in subsequent analyses. The approximate dimensions of the marginal osteophyte is outlined in red and indicated
with an arrow. High magniﬁcation images showing typical cartilage pathological changes in Area 1 and 2 in sham vs MEN joints are shown on the right. (B) Modiﬁed Mankin score
of tibial cartilage and (C) percentage of the subchondral region that was bone, in Area 1 and 2 of sham and MEN joints (line¼median, box¼ upper and lower quartiles, whis-
kers¼ tenth to ninetieth percentile, circles¼maximum and minimum values; n¼ 6 in both groups). (D) Representative sections showing immuno-localization of SOST (brown
stain) in Area 2 articular cartilage and adjacent subchondral bone in sham and MEN joints. (E) Loss of SOST immunostaining in cartilage from MEN and bone from sham joints by
pre-absorption of the antibody with recombinant SOST. (F) The percentage of cells in different areas of sham and MEN joints that were immunopositive for SOST (mean 95%
conﬁdence intervals; n¼ 6 in both groups). Signiﬁcant difference between sham and MEN joints in different regions are indicated by a bar with the P-value given above.
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noglycan (GAG) into the media was measured using dimethyl-
methylene blue and normalised to the explant wet weight36.
RNA extraction, reverse transcription (RT) and real-time
quantitative polymerase chain reaction (PCR)
Approximately 100 mg of frozen ovine or human cartilage were
fragmented in aMikro-Dismembrator (Braun Biotech International,
Melsungen, Germany). Total RNA was extracted with TRIzol and
isolated using the RNeasy kit (Qiagen, Australia) including an on-
column DNase I (Qiagen) digestion, quantiﬁed with a Nanodrop
1000 spectrophotometer (Thermo Scientiﬁc, Waltham, USA), and
samples with a 260/280 ratio> 2.0 used for RT. Changes in mRNA
expression were quantiﬁed using real-time RT-PCR as described37
using speciﬁc primer sets (Table I). The “housekeeping genes”
examined (glyceraldehyde 3-phosphate dehydrogenase, hypo-
xantine phsophoribosyltransferase (GAPDH, HRPT), b-actin and
ubiquitin) were all regulated by one or more of the experimental
conditions (data not shown), and therefore samples were normal-
ised using equal amounts of total RNA as recommended38,39, and
effects of treatment expressed as fold change from control.
Statistical analysis
Data is reported as mean with 95% conﬁdence intervals (lower,
upper). Ordinal data (histological scoring) is presented graphically in
box plots showing median, upper and lower quartile (box), tenth to
ninetieth percentile (whiskers) and maximum and minimum values
(open circles). Changes in the number of positively stained cells, and
the fold change in gene expression or GAG release are presented
graphically as mean with 95% conﬁdence intervals. Because some
data (e.g., gene expression) was not normally distributed, all treat-
ment effects were assessed using non-parametric analysis (Man-
neWhitney U test) with P< 0.05 considered signiﬁcant.
Results
SOST is increased in cartilage but decreased in subchondral bone in
OA
MEN induced focal OA-like change in the sheep, including loss of
cartilage proteoglycan, cartilage surface ﬁbrillation and partial
thickness erosion, and marginal osteophytosis [Fig. 1(A)]. Signiﬁ-
cant cartilage changes were restricted to the region previously
protected by the meniscus that is subjected to high focal loading inTable I
Primer sequences used for PCR analysis of gene expression
Species Gene Accession # Tm (C) Product size (b
Ovine ACAN U76615 58 105
ADAMTS4 NM181667 60 149
ADAMTS5 AF192771 55 97
COL2A1 X02420 55 154
MMP1 AF267156 55 122
MMP13 AY091604.1 58 113
TIMP1 S67450 57 265
Ovine/human TIMP3 NM174473 57 286
CTNNB1 NM_001076141.1 58 105
DKK1 XM_580572.4 58 116
WISP1 XM_585338.3 58 290
LRP5 AB257751.1 58 335
LRP6 AB257752.1 58 220
SOST NM008078.1/X
M588605.3
58 71meniscectomised joints (Area 2 e score 3.2 (2.4, 3.9) vs 10.4 (8.6,
12.2); P< 0.001), with no change in Area 1 [Fig. 1(B)]. In association
with the overlying cartilage damage there was increased sub-
chondral bone in Area 2 in meniscectomised joints [Fig. 1(C), 80.1%
(74.1, 86.1) vs 92.8% (86.4, 99.2); P¼ 0.018].
SOST was immuno-localised to osteocytes and their canaliculi in
the subchondral plate [Fig.1(D)] and deeper TB (not shown) in sham-
operated joints. This staining was speciﬁc as demonstrated by lack of
signal when IgG was substituted for the primary antibody (not
shown) or pre-absorption with rhSOST prior to immunostaining
[Fig. 1(E)]. There was no difference in the number of SOST-positive
osteocytes between Area 1 and 2 in sham-operated joints, although
both were greater than TB [Fig. 1(F); Area 1¼71.0% (66.8, 77.2), Area
2¼ 67.9% (65.1, 70.7) vs TB 29.5% (15.9, 43), P¼ 0.002 for both]. There
was little SOST staining of chondrocytes in the non-calciﬁed cartilage
in sham-operated joints [Fig. 1(D)], while some hypertrophic chon-
drocytes in the calciﬁed cartilage were positive (not shown). In
meniscectomised joints osteocyte SOST staining intensity decreased
in Area 2 subchondral bone with little change in Area 1 [Fig. 1(D)] or
TB (not shown). The percentage of SOST-positive osteocytes in sub-
chondral bone decreased inmeniscectomised joints [Fig.1(F)] in Area
1 (57.9% (49.5, 66.3), P¼ 0.019 vs sham) and Area 2 (46.2% (32.7, 59.8),
P¼ 0.012 vs sham). In contrast, there was a marked increase in SOST
staining intensity [Fig. 1(D)], and the number of positive
chondrocytes in the non-calciﬁed cartilage only in Area 2 in menis-
cectomised joints [Fig. 1(F); 15.0% (7.2, 22.9) vs 42.3% (23.1, 61.4);
P¼ 0.001].
We conﬁrmed the positive chondrocyte SOST immunostaining
observed in sheep, in DMM-induced OA in mice and in late stage
humanOA (Fig. 2). In sham-operatedmouse joints, therewasnoSOST
staining in non-calciﬁed articular cartilage chondrocytes, although
almost all chondrocytes in the calciﬁed cartilage were immuno-
positive [Fig. 2(A)]. At 2weeks post-DMM, scattered chondrocytes in
the non-calciﬁed cartilage became SOST positive, and there was an
increase in staining intensity in the calciﬁed cartilage [Fig. 2(A)]. In 3/
9 human OA tibial plateaux, chondrocytes in the superﬁcial cartilage
zones, often in clusters, stained strongly for SOST [Fig. 2(B)]. The
antibody speciﬁcity in human samples was conﬁrmed by osteocytes
in subchondral and TB having typical canalicular SOST staining, and
the lack of staining when IgG was substituted for the primary anti-
body [Fig. 2(B)].Chondrocytes express SOST mRNA and it is regulated by IL-1
We investigated whether the SOST staining in chondrocytes was
associated with local synthesis by the chondrocytes rather thanp) Forward Reverse
TCACCATCCCCTGCTACTTCATC TCTCCTTGGAAATGCGGCTC
AACTCGAAGCAATGCACTGGT TGCCCGAAGCCATTGTCTA
GCATTGACGCATCCAAACCC CGTGGTAGGTCCAGCAAACAGTTAC
TGACCTGACGCCCATTCATC TTTCCTGTCTCTGCCTTGACCC
CATTCTACTGACATTGGGGCTCTG TGAGTGGGATTTTGGGAAGGTC
TGACAGGCAGACTTGATGATAAC CATTTTGGACCACTTGAGAGTTC
GGT TCAGTGCCTTGAGAGATGC GGGATAGATGAGCAGGGAAACAC
CTTCCTTTGCCCTTCTCTACCC TCTGGTCAACCCAAGCATCG
AATGGCTTGGAATGAGACTGCT CCAGAGTGAAAAGAACGATAGC
TCTTCGCTCATCAGACTGTGCTG AGCCTTTTCTCCTGTGCTTGGTG
ATCAAGGTGGGGAAGAAGTG GAGAAGTCAGGGTAGGAGTC
ACTTCATCTACTGGACCGACTG CACATCGTTGTTGTTGGTGTC
CGTCAAGTAGTTCATCAAGCACC GCATAGTCACTGTCACACACATCTG
ACCACCCCTTTGAGACCAAAG GGTCACGTAGCGGGTGAAGT
Fig. 2. (A) SOST immunostaining in mouse knee joints 2 weeks after sham surgery or DMM. Positive SOST staining (brown) was seen in osteocytes (black arrow) and hypertrophic
chondrocytes in calciﬁed cartilage (yellow arrow) in sham and DMM joints. Chondrocytes in the non-calciﬁed articular cartilage (red arrow) were only immunopositive in DMM
joints. (B) Representative sections of human osteoarthritic cartilage and TB showing clusters of chondrocytes in the ﬁbrillated surface and osteocytes that were immunopositive for
SOST (brown stain), with no positive staining observed in serial sections with equal concentration of (1.25 mg/ml) of IgG as a negative control. (C) Ethidium bromide stained gels
Expression of SOST mRNA demonstrated by PCR, in two of six human OA articular cartilage samples.
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mRNA in chondrocytes in ovine cartilage, and from 2/6 human
patients tested [Fig. 2(C)]. We examined whether the increase
chondrocytes SOST in OA might be due to upregulated expressionby inﬂammatory cytokines. In preliminary studies equivalent
maximal GAG release from cartilage occurred with 10 ng/ml IL-1a
and 100 ng/ml TNFa (data not shown). At these maximally effective
doses, IL-1a induced a 9-fold (6.6, 10.7) up-regulation of SOST
Fig. 3. (A) Quantitative PCR analysis of SOST gene expression in ovine articular cartilage explants cultured for 24 and 48 h in serum free media alone (Control) or in the presence of
IL-1a (10 ng/ml) or TNFa (100 ng/ml). Data is expressed as fold change in expression compared with untreated control cultures at each time point (mean 95% conﬁdence intervals;
n¼ 6 per treatment per time point). Signiﬁcant differences compared to control culture at the same time are indicated by the P-value above the given culture condition. (B)
Immuno-localization of SOST in ovine articular cartilage explants cultured for 24 h in serum free media alone (Control) or in the presence of IL-1a (10 ng/ml). Chondrocytes with
positive SOST staining (brown stain) are indicated with red arrows.
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remained elevated at 48 h (1.8-fold (1.3, 2.2); P¼ 0.093). This IL-
1-induced increase in SOST mRNA was accompanied by increased
chondrocyte SOST immuno-localization [Fig. 3(B)]. In contrast,
TNFa did not alter chondrocyte SOST expression in ovine cartilage
explants at either 24 or 48 h [Fig. 3(A)].
Wnt-b-catenin signalling is altered in meniscectomy-induced OA in
sheep
In light of SOST being an antagonist ofWnt-b-catenin signalling in
bone, we examined whether WISP-1, a down-stream indicator of
increased b-catenin activity, was co-ordinately decreased in the
sheep OA model. In sham-operated joints WISP-1 was immuno-
localised to osteocytes in the subchondral bone plate [Fig. 4(A)] and
TB (not shown). There was no difference in the number of WISP-1-
positive osteocytes between bone regions in sham-operated joints
and no change following MEN [Fig. 4(B)]. WISP-1 was immuno-
localised to the chondrocytes in the superﬁcial layer in sham-
operated joints [Fig. 4(A)], and some hypertrophic chondrocytes in
the calciﬁed cartilage (not shown). Following MEN there was no
change in intensity or distribution of chondrocyteWISP-1 staining in
Area 1, however chondrocytes through the depth of the non-calciﬁed
cartilage showed strong staining in Area 2 [Fig. 4(A)]. The percentageof WISP-1-positive chondrocytes increased only in Area 2 of menis-
cectomized joints [22.0% (15.5, 28.4) vs 56.6% (38.0, 75.2); P¼ 0.006;
Fig. 4(B)].SOST regulates gene expression in normal cartilage
The co-localised increase in chondrocyte SOST and WISP-1
staining in OA cartilage (Area 2) were not consistent with the
purported role of SOST as an inhibitor of Wnt-b-catenin signalling.
We therefore investigated the effect of SOST on chondrocyte
expression of WISP1 as a marker of b-catenin activity, as well as
a number of other Wnt-signalling genes in normal ovine cartilage
explants. Treatment with 25 or 250 ng/ml rhSOST for 24 h did not
regulate WISP-1 expression (not shown). However, signiﬁcant
suppression ofWISP-1 as well as b-catenin (CTNNB1), LRP5 and LRP6
was noted after 48 h incubation with both doses of SOST [Fig. 5(B)].
Concordant with this inhibition of Wnt signalling at 48 h, SOST
decreased collagen type II (COL2A1), aggrecan (ACAN) and tissue
inhibitor of metalloproteinase 1 (TIMP1) mRNA expression by
a similar level at both doses [Fig. 5(B)]. MMP1 and disintegrin and
metalloproteinase with thrombospondin repeat 4 (ADAMTS4)
mRNA levels were not signiﬁcantly altered by SOST suggesting that
the effects were not due to generalised cell toxicity. MMP13
Fig. 4. Representative sections of ovine tibial plateau from sham and MEN joints, showing (A) WISP-1 immuno-localization (brown stain). (B) The percentage of cells in different
areas of sham and MEN joints that were immunopositive for WISP-1 (mean 95% conﬁdence intervals; n¼ 6 in both groups). Signiﬁcant differences between sham and MEN joints
in different regions are indicated by a bar with the P-value given above.
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and TIMP3 were dose-dependently decreased.
SOST inhibits IL-1-induced cartilage degradation
The results in normal cartilage suggest that indeed SOST is
a negative regulator of Wnt-b-catenin signalling and activity in
chondrocytes. However SOST had effects on chondrocyte gene
expression that would be considered “anti-anabolic” (decreased
ACAN and COL2), “pro-catabolic” (decreased TIMP1 and TIMP3) as
well as “anti-catabolic” (decreasedMMP13 and ADAMTS5). In order
to investigate the effect of SOST in an environment where cartilage
catabolism is augmented, we co-cultured explants for 48 h with
SOST in the presence of 10 ng/ml IL-1a. IL-1a induced the expected
changes in chondrocyte gene expression, decreasing ACAN and COL2
while increasingMMP1,MMP13, ADAMTS4 and ADAMTS5 [Fig. 6(A)].
These IL-1-induced changes were accompanied by increased GAG
release and a concordant loss of toluidine blue staining of the
cartilage [Fig. 6(B)]. Importantly, SOST dose-dependently decreased
IL-1a-induced GAG release into the media, with over 50% reduction
at 250 ng/ml [Fig. 6(B), P< 0.001], albeit that it still remainedelevated compared with control cultures. SOST still decreasedWnt-
b-catenin signalling in the presence of IL-1a as indicated by the
reduction inWISP-1 expression with the 250 ng/ml dose (0.45-fold
(0.25, 0.65), P¼ 0.009). SOSTalso inhibited expression of otherWnt-
b-catenin signalling molecules in the presence of IL-1, with CTNNB1
reduced at both 25 ng/ml (0.35-fold (0.1, 0.6); P¼ 0.003) and
250 ng/ml (0.4-fold (0.2, 0.6); P¼ 0.005), and the other genes at
250 ng/ml only (LRP5 0.4-fold (0.2, 0.6), P¼ 0.029; LRP6 0.25-fold
(0.01, 0.49), P¼ 0.12). This inhibition of Wnt-b-catenin signalling
and GAG release by SOST was associated with signiﬁcant down-
regulation of IL-1a-induced chondrocyte expression of MMP1,
MMP13, ADAMTS4 and ADAMTS5, while the IL-1-induced inhibition
of ACAN and COL2 remained unchanged [Fig. 6(C)].
Discussion
Canonical Wnt signalling and increased b-catenin activity have
been implicated in the process of cartilage degradation in OA11,40.
The current data from the sheep MEN model of OA supports these
previous studies, showing elevated chondrocyte WISP-1 staining.
Our detailed regional analysis enabled us to demonstrate that this
Fig. 5. Quantitative PCR analysis in ovine articular cartilage explants cultured for 48 h in serum free media 25 or 250 ng/ml recombinant human SOST. Expression of (A) Wnt-
b-catenin pathway genes, and (B) matrix protein, metalloproteinase and tissue inhibitor genes. Data is expressed as fold change in expression compared with untreated control
cultures (mean 95% conﬁdence intervals; n¼ 22 replicates from three individual experiments). Signiﬁcant differences compared to control culture are indicated by the P-value.
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area of cartilage degradation, and was unaltered in the remaining
cartilage or the subjacent bone. Previous studies have suggested
conﬂicting roles for DKK1 and sFRP3 in regulating cartilage and
bone changes in animal models of OA14,17. SOST is also a potentWnt
antagonist and a key regulator of bonemetabolism, but no previous
publications have investigated whether it plays a role in global OA
joint pathology. We have for the ﬁrst time demonstrated an
increase in SOST in chondrocytes restricted to the focal area of
cartilage degradation in post-traumatic OA. In addition, we found
a differential regulation in cartilage and bone, with a decrease in
osteocyte SOST staining associated with increased subchondral
plate thickening. Furthermore, we show that chondrocytes them-
selves express SOST which can be regulated by IL-1a but not TNFa.
SOST could act as an inhibitor of Wnt-b-catenin signalling in
chondrocytes in vitro, and in the presence of IL-1a signiﬁcantly
regulate expression of cartilage matrix proteins, MMPs, ADAMTS
and TIMPs, with a net result of reducing IL-1a-induced aggreca-
nolysis. Taken together, this data suggests that changes in SOSTmay
play a role in the pathological progression of OA, promoting sub-
chondral bone sclerosis but potentially inhibiting cartilage
proteolysis.
Given that SOST is a potent antagonist of the Wnt-b-catenin
pathway, it is difﬁcult to reconcile the coincident increase in SOST
and WISP-1 in OA cartilage. One possible explanation is that
b-catenin is being activated in chondrocytes by prostaglandin-E2,independent of Wnt-signalling as described in other cell types41.
Canonical regulation of b-catenin byWnts is complex, with levels of
different Wnts, receptors, inhibitors and intracellular ligands all
contributing42. A decrease in one of these components may be
offset by the increase in another, with a net abrogation of the
expected action. Nevertheless, the increase in SOST in OA chon-
drocytes should be acting to decrease canonical signalling, and
most data suggests that elevated chondrocyte b-catenin has a pro-
catabolic effect on cartilage, stimulating MMP and ADAMTS
synthesis via increased WISP-111,16, and promoting chondrocyte
hypertrophy which is associated with OA cartilage pathology6,8. As
such, elevated chondrocyte SOST is likely to be at least partially
chondroprotective, and in its absence an even greater increase in
chondrocyte b-catenin activity, WISP-1 and associated cartilage
degradationwould ensue. Our in vitro data support this hypothesis,
with down-regulation of b-catenin signalling, MMP and ADAMTS
expression by SOST. Consistent with a beneﬁcial effect of Wnt
antagonism, elevated circulating levels of DKK1 are negatively
associated with serum markers of cartilage degradation in human
OA13. However, it would appear that some “appropriate” level of
chondrocyte b-catenin activity is needed to maintain normal
cartilage, as excessive inhibition12 and in vitro treatment with
DKK116, can induce chondrocyte apoptosis and cartilage
breakdown.
The effect of SOSTonWnt signalling in OA cartilage/chondrocytes
will be dependent on its binding to Lrp5/6. DKK1 can displace SOST
Fig. 6. Effect of recombinant SOST (25 or 250 ng/ml) on ovine articular cartilage cultured for 48 h in the presence of 10 ng/ml IL-1a. (A) Quantitative PCR analysis demonstrating the
effect of IL-1 alone on the expression of matrix proteins, metalloproteinase and tissue inhibitors. Data is expressed as fold change in expression compared with untreated control
cultures (mean 95% conﬁdence intervals; n¼ 17 replicates from three individual experiments). (B) Representative images of toluidine blue stained sections of cartilage explants
cultured for 48 h 10 ng/ml IL-125 or 250 ng/ml SOST. Sulphated GAG release from the same cartilage cultures expressed as fold change in expression compared with untreated
control cultures (mean 95% conﬁdence intervals; n¼ 18 replicates from three individual experiments). (C) Quantitative PCR analysis demonstrating the effect of 25 or 250 ng/ml
SOST in the presence 10 ng/ml IL-1, on the expression of matrix proteins, metalloproteinase and tissue inhibitors. Data is expressed as fold change in expression compared with IL-1
alone (mean 95% conﬁdence intervals; n¼ 17 replicates from three individual experiments). Signiﬁcant differences compared to control culture are indicated by the P-value above
or below the speciﬁc treatment. Differences between particular treatments connected by a bar are indicated by the P-value.
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OA cartilage could potentiate effects of SOST outside the Lrp5/6-b-
catenin pathway. SOST binds to Lrp4, and hypomorphic mutations in
Lrp4 result in skeletal abnormalities in mice including poly-
syndactyly, possibly through interfering with BMP signalling43. SOST
also functions as a BMP antagonist by inhibiting secretion from cells
in which it is co-expressed18, and BMPs have potent effects on
chondrogenesis, chondrocyte maturation and anabolism44, as well
as increasing DKK1 expression45. Over expression of human SOST in
mice leads not only to decreased bone density through inhibition of
Wnt-b-catenin signalling, but also syndactyly consistent with inhi-
bition of BMPs46. SOST can rapidly activate extracellular signal-
regulated kinase1/2 signalling in osteoblasts by an undeﬁned
pathway24. These non-Wnt-dependent pathways may contribute to
the effect of elevated SOST in OA chondrocytes, possibly promoting
rather than inhibiting cartilage degradation.
Control of SOST expression by different regulatory elements in
the proximal promoter is dependent on cell type46. Our in vitro data
demonstrates that, at doses that induce cartilage degradation, IL-1a
but not TNFa increased SOST expression. The lack of effect of TNFa
on SOST mRNA levels in chondrocytes is interesting in light of the
signiﬁcant up-regulation of SOST by TNFa in osteoblasts24, consis-
tent with cell-speciﬁc regulation. Regulation of chondrocyte type II
collagen and MMP expression by IL-1 has been reported to be
independent of Wnt-b-catenin signalling11,47. Nevertheless both IL-
1 and TNF can regulate expression and activity of the Wnt-b-cat-
enin pathway16,24. Our data demonstrating a distinct difference
between IL-1a and TNFa in SOST regulationwhile the two cytokines
have similar effects on ACAN, COL2, MMP and ADAMTS expression
(data not shown), is consistent with cytokine-driven cartilage
catabolism being independent of Wnt-b-catenin. Chondrocyte-
derived IL-1 has been implicated in OA cartilage degradation48,
which could potentially account for the increase in SOST in OA
cartilage. However, the very focal nature of the cartilage changes
and altered SOST expression in our sheep OA model, suggests
a more localized regulatory mechanism such as mechanical
loading. In bone, SOST expression is strongly regulated by
mechanical loading22,49, and the decrease in SOST protein in the
subchondral plate following MEN is consistent with these previous
studies. Despite the overlying cartilage also experiencing increased
focal compressive loading in the MEN model, an increase rather
than decrease in chondrocyte SOST was seen. This may suggest
different mechano-regulation of SOST in osteocytes vs chon-
drocytes. The reason that only w30% of OA human cartilage
samples expressed SOST mRNA and protein is unclear but could be
associated with differences in the degree of synovial inﬂammation
between patients. It may also be associated with disease chronicity
and activity in end-stage human OA, with the normal SOST staining
of osteocytes in human samples perhaps indicative of little active
remodelling at the time of joint replacement. Nevertheless, the fact
that articular chondrocytes expressed SOST in OA in all three
species suggests it is a common pathophysiological mechanism,
and future studies should examine the temporal changes in SOST
over the course of OA initiation and progression.
In conclusion, we have demonstrated that contrary to being an
osteocyte-speciﬁc product, SOST is expressed by articular chon-
drocytes and is regulated by IL-1a. Importantly, chondrocyte SOST
is focally increased in cartilage in OA while being decreased in the
subjacent subchondral bone. While the role of SOST in regulating
bone metabolism has been well established, we show for the ﬁrst
time that SOST is biologically active in chondrocytes, not only
inhibiting Wnt-b-catenin signalling and catabolic MMP and
ADAMTS expression, but also decreasing mRNA levels of keymatrix
components and enzyme inhibitors. Despite this mixed effect,
SOST dose-dependently inhibited IL-1a-stimulated cartilageaggrecanolysis in vitro. These results implicate SOST in regulating
the OA disease processes in both bone and cartilage, but suggest
opposing effects by promoting disease-associated subchondral
bone sclerosis while inhibiting degradation of cartilage. Increasing
Wnt-b-catenin activity using antibodies to SOST (and DKK1) has
potential in treating osteoporotic and inﬂammatory bone loss50,51.
While it is unlikely such therapeutic agents will enter cartilage to
regulate chondrocyte SOST, given the multiple mechanisms of
action of SOST in joint tissues, it will be important to determine
what effect its inhibition may have on progression of both bone and
cartilage changes in OA in vivo.
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